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Abstract
Background: Dilated cardiomyopathy (DCM) and myxomatous mitral valve disease (MMVD) are the most common
diseases noted in dogs. Although their pathogenesis varies, both include a significant enlargement of the left atrium.
The study was carried out on left atrial specimens obtained from 56 dogs, including those from 34 dogs with clinically
diagnosed MMVD, 15 dogs with DCM and 7 dogs without heart disease (control group). Dogs in the MMVD and the
DCM groups presented with left atrial enlargement and stage D heart failure. The specimens underwent
immunohistochemical examination using desmin, vimentin, periostin and caspase-3 antibodies.
Results: There were alterations in the expression of the studied proteins in the study groups compared to the control
group. The changes included: irregularity of desmin cross-striation and desmosomes, a higher amount of vimentin-
positive cells, a change in the periostin expression pattern from cytoplasmic to extracellular, and a lower expression of
caspase-3. The alterations were more pronounced in the DCM group than in the MMVD group.
Conclusions: During heart failure, the pattern of desmin, vimentin, periostin and caspase-3 expression alters in the left
atrium, regardless of the cause. The changes are more pronounced in dogs with DCM than in dogs with MMVD and
similar left atrial enlargement, suggesting that volume overload may not be the only cause of myocardial changes in DCM.
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Background
Dilated cardiomyopathy (DCM) is a disease of various
aetiologies diagnosed mainly in large and giant breed dogs.
It is characterised by an enlargement of all the heart
chambers without other concurrent heart diseases [1–6].
Myxomatous mitral valve disease (MMVD) involves a
progressing degeneration of the valve leaflets resulting in
mitral regurgitation and left atrial and ventricular
enlargement [7].
The majority of research concerning heart failure result-
ing from these diseases focuses on changes occurring in
the ventricles. However, current research suggests that
myocardial remodelling is more pronounced in the left
atrium than the left ventricle [8, 9].
Although both DCM and MMVD are accompanied by a
considerable enlargement of the left atrium (LA), our
previous study [10] showed significant differences in the
remodelling of the LA wall in these two diseases. DCM is
accompanied by a more pronounced interstitial fibrosis
with less distinct perivascular fibrosis and myocardial arter-
ial narrowing than MMVD. Additionally, the cardiomyo-
cyte degenerative changes are more severe in DCM than in
MMVD. Hence, we decided that it might be useful to assess
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and compare the expression of various cell markers of car-
diomyocyte and interstitial tissue in these diseases. Since
myocardial remodelling affects not only cardiomyocytes
but also the interstitial tissue, we assessed various cell
markers: desmin as a standard cardiomyocyte marker,
vimentin as a typical cell marker expressed in mesenchymal
cells, periostin as a novel marker for myocardial remodel-
ling, and caspase-3 as a marker of cell apoptosis. This pre-
liminary study is the first step toward extensive research on
a wide variety of cell markers.
Desmin is a protein that builds intercalated discs. It is
the main component of the cardiomyocyte cytoskeleton
and forms the intermediate filament. Due to its role in
the formation of striation within the myocardium, des-
min plays an important part in the normal functioning
of the myocardium by forming striation. In the course of
heart failure, the structure of the cardiomyocyte is com-
promised and there is a disorganisation of desmin fila-
ments and loss of cross striation [11–14].
Vimentin builds intermediate filaments of mesenchymal
cells and is produced in fibroblasts, macrophages, endo-
thelial cells and smooth muscle cells. In normal cardiac
tissue, vimentin-positive cells are spread among cardio-
myocytes, forming a delicate stroma, the amount of which
increases with progressing heart failure [12, 14].
Periostin expression is particularly high in collagen-rich
connective tissue subjected to mechanical stress e.g. heart
valves [15]. In a normal heart, periostin plays a role in the
morphogenesis of heart valves. It is also produced by fibro-
blasts and ventricular cardiomyocytes during heart failure
and over the past few years has served as a marker of myo-
cardial remodelling in volume overload in humans and as a
potential new target for treatment possibilities [16–18].
In quiescent cells, caspases exist as inactive zymogens
that are readily activated by autocatalytic processes or by
other caspases following a death signal [19]. The activation
of caspase-group proteins is crucial during apoptosis, which
is thought to be one of the factors causing progressing heart
failure of various aetiologies [20, 21].
The objectives of the study were: (1) the assessment
and comparison of the expression of desmin, vimentin,
periostin and caspase-3 in the left atrial myocardium in
dogs with DCM and MMVD showing severe left atrial
enlargement; (2) comparison of those results with the
results from a group of dogs without heart disease; (3)
the evaluation of the correlation between the expression
of the examined proteins and heart remodelling based
on the histological examination.
Methods
Population study and inclusion criteria
The study was conducted on left atrial specimens ob-
tained from 56 dogs divided into 3 groups: dogs present-
ing with dilated cardiomyopathy (DCM group; n = 15),
dogs with left atrial enlargement due to myxomatous
mitral valve disease (MMVD group; n = 34) and dogs
that underwent euthanasia due to causes not related to
cardiovascular system and that did not show intravital or
post-mortem features of cardiorespiratory disease and
LA enlargement (control group; n = 7).
Dogs met the inclusion criteria if they had an enlarged
left atrium as defined by an echocardiographic examin-
ation (left atrial (LA)-to-aortic root (Ao) diameter ratio;
LA/Ao >1.7 [22]), which was confirmed in the post-
mortem examination. A dilation of the left ventricle and
a decreased fractional shortening (FS < 20%), both noted
during the echocardiographic examination [3, 5, 6], with
normal or type 1 mitral valve lesions (according to
Whitney [23]) were required to classify dogs in the
DCM group. Dogs in the MMVD group were required
to have a preserved left ventricular systolic function
(FS > 20%, noted by echocardiographic examination)
with type 3 or 4 mitral valve lesions (according to Whit-
ney [23]). At the time of death or euthanasia, all the
dogs in the DCM and MMVD groups presented with
stage D heart failure (according to the ACVIM Consen-
sus Statement [24]).
Clinical and post-mortem examination
Fourty two dogs underwent a standard clinical and car-
diological examination with ECG, an echocardiographic
examination and 24-h ECG (Holter) monitoring in cases
where rhythm disturbances were suspected as described
in our previous study [10]. After the examination, dogs
in the DCM and the MMVD group underwent appropri-
ate treatment to reduce the effects of progressive heart
failure and/or arrhythmias, and were checked every
6 months or more frequently if necessary until the mo-
ment of death or euthanasia. All the dogs in the DCM
and the MMVD group died or were euthanized within
5 years of diagnosis.
In 14 cases, some or all the results of the cardiac
examination were not available. In those cases, a particu-
lar emphasis was put on the post-mortem examination
to confirm the inclusion of the dogs in the DCM,
MMVD, or control group.
The results of the echocardiographic examination (left
atrial and left ventricular enlargement) were confirmed
during the post-mortem examination, and the type of
mitral valve lesion was assessed. Heart measurements were
taken using a manual 150 mm Beerendonk caliper, accurate
to the nearest 1/20 mm. The measurements were taken in
planes compatible with those used during the echocardio-
graphic examination. The left atrial diameter was related to
the diameter of the aorta (as in LA/Ao ratio) and the left
ventricular internal diameter and wall thickness were mea-
sured beneath the mitral valve with the omission of the
papillary muscles. The type of mitral valve lesion according
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to Whitney [23] was determined based on the thickness of
the valve leaflets and tendinous chords. Specimens from
the left atrial wall were collected from each dog for further
histopathological and immunohistochemical analysis. The
specimens were collected in the dorso-ventral plane from
the middle portion of the atrial free wall, at the same site in
all the dogs.
Histopathological examination
The specimens were fixed in 7% buffered formalin, dehy-
drated, embedded in paraffin blocks and sectioned at
4 μm. Each specimen was randomly assigned a number to
allow a blinded examination. The specimens were stained
with haematoxylin-eosin and Masson-Goldner trichrome
and evaluated for interstitial and perivascular fibrosis, car-
diomyocyte degeneration, intramyocardial arterial narrow-
ing and inflammatory infiltrates as described in our
previous study [10]. The interstitial fibrosis was evaluated
after superimposing a 16-field grid over the digital image
and counting the number of fields that showed the pres-
ence of fibrosis [4, 10]. The severity of perivascular fibrosis
was scored from 0 (no fibrosis) to 3 (severe fibrosis) [10].
Cardiomyocyte degenerative changes (abnormal cell nu-
clei, loss of striation and changes in the structure of the
cardiomyocytes) were scored from 0 (normal myocardium
or changes affecting <25% of myofibres) to 3 (changes af-
fecting >75% of myofibres) [10]. Intramyocardial arterial
narrowing was assessed using the lumen area ratio (LAR;
the luminal area of the vessel divided by the total vessel
area, not including the adventitia) [10, 25]. Inflammatory
infiltrates were evaluated according to the number of in-
flammatory cells in a high power field [10]. Each of the
features was evaluated in 20 randomly chosen fields per
slide (for interstitial fibrosis, cardiomyocyte degeneration
and inflammatory infiltrates) or in at least 10 vessels per
slide (for perivascular fibrosis and intramyocardial arterial
narrowing). An average score was counted for each feature
in every specimen.
Immunohistochemical examination
The paraffin sections were placed on silanized microscope
slides and underwent a standardised immunohistochemical
staining procedure using Autostainer Link48 (Dako-
Cytomation, Glostrup, Denmark). First, deparaffinization,
rehydration and antigen retrieval was performed using
EnVision FLEX Target Retrieval Solution (97 °C, 20 min) in
PT-Link. Activity of endogenous peroxidase was blocked by
5 min incubation with EnVision FLEX Peroxidase-Blocking
Reagent (DakoCytomation). The sections were overlayed
with primary antibodies, including a mouse monoclonal
anti-desmin-clone D33 (DAKO, Danmark); a mouse mono-
clonal anti-vimentin-clone V9 (DAKO, Danmark); rabbit
polyclonal anti-periostin (Abcam, UK) and a mouse
monoclonal anti-caspase-3 – clone 3CSP03 (Abcam, UK)
for 20 min. No secondary antibodies were used.
Then slides were incubated with EnVision FLEX/HRP
(20 min). 3,3′-diaminobenzidine (DAB, Dako) was uti-
lized as the peroxidase substrate and the sections were
incubated for 10 min. Finally, all sections were counter-
stained with EnVision FLEX Hematoxylin (Dako) for
5 min. After dehydration in graded ethanol concentra-
tions (70%, 96%, 99,8%) and in xylene, slides were closed
with coverslips in Dako Mounting Medium (DakoCyto-
mation). Specimens from the control group collected for
the analysis of the expression of desmin, vimentin and
caspase-3 served as positive controls. Specimens of heart
valves stained according to the abovementioned protocol
were used as positive controls for the expression of peri-
ostin; sections immunostained in the absence of a pri-
mary antibody were used as negative controls.
Photomicrographs of the examined tissues were sub-
jected to computer-assisted image analysis, using a com-
puter coupled to an optical Olympus BX53 microscope,
equipped with an Olympus Color View IIIu digital cam-
era (Olympus, Japan) and cell^A software (Olympus Soft
Imaging Solution GmbH, Germany).
Since in the literature the immunohistochemical ex-
pression of the examined markers in the myocardium is
reported mainly descriptively [11, 14, 26], we evaluated
the pattern of expression for each cell marker. Moreover,
to allow a semi-quantitative comparison of the examined
markers and their correlation with myocardial remodel-
ling, their expression in cardiomyocyte and interstitial
tissue was appraised in 10 randomly chosen high power
fields using a three step approach: 1) the intensity of ex-
pression (scored from 0–no expression, to 3–strong ex-
pression), 2) the percentage of marker-positive cells
within a high power field, 3) the modified semiquantita-
tive immune-reactive score (IRS) scale according to
Remmele [27]. The latter takes into account both the
intensity of the expression and the percentage of positive
cells. Additionally, the expression of desmin within the
desmosomes was scored from 0 (no expression) to 3
(strong expression). An average score from 10 examined
fields was counted for each feature.
Statistical analysis
The normality of the data was evaluated using Shapiro-
Wilk analysis. The obtained data underwent statistical ana-
lysis using the Kruskal-Wallis rang analysis and Spearman’s
correlation test using StatisticaPL for Windows (StatSoft,
Poland). Statistical significance was set at p ≤ 0.05.
Results
The DCM group consisted of 13 males and 2 females, aged
from 4 to 11 years (median 8 years), weighing from 30 to
45 kg (median 31 kg), and included eight Doberman
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Pinchers, four German Shepherds, two boxers and one
Great Dane. The MMVD group consisted of 21 males and
13 females, aged from 8 to 19 years (median 14 years),
weighing from 5 to 35 kg (median 10.5 kg), and included
23 mixed-breed dogs, five dachshunds, two miniature
Pinchers and one dog of each breed: Black Russian Terrier,
Shar-Pei, Cairn Terrier and the American Staffordshire Ter-
rier. The control group consisted of 5 males and 2 females,
aged from 1 to 12 years (median 10 years), weighing from 5
to 25 kg (median 5 kg), including three mixed-breed dogs
and one dog of each breed: miniature Schnauzer, German
Shepherd, dachshund, boxer.
There was no significant difference between the LA/
Ao ratio in both examined groups in either the echocar-
diographic or post-mortem examination (p > 0.05).
Immunohistochemical examination
The results of the protein expression in each group of dogs
are presented in Tables 1 and 2 and Figs. 1, 2, 3 and 4
Desmin
In the normal myocardium, both striation and desmosomes
are well visible. In enlarged left atria, the striation becomes
irregular, unclear and the desmosomes are faint or do not
stain. The changes in the desmin staining pattern are more
pronounced in the DCM dogs than in the MMVD dogs
with significantly lower staining intensity and lower
Remmele scores in the first group (Tables 1 and 2, Fig. 1).
The intensity of the desmin expression showed a negative
correlation with the enlargement of the cardiomyocyte nu-
clei (p < 0.05, r = −0.53), loss of cardiomyocyte striation (p
< 0.05, r = −0.48) and cardiomyocyte degeneration (p < 0.05,
r = −0.53). The percentage of desmin-positive cells showed
a positive correlation with the enlargement of the cardio-
myocyte nuclei (p < 0.05, r = 0.37), loss of cardiomyocyte
striation (p < 0.05, r = 0.49) and cardiomyocyte degener-
ation (p < 0.05, r = 0.46). The desmin Remmele score
showed a negative correlation with the enlargement of the
cardiomyocyte nuclei (p < 0.05, r = −0.44), loss of cardio-
myocyte striation (p < 0.05, r = −0.38) and cardiomyocyte
degeneration (p < 0.05, r = −0.45). The desmosome desmin
score showed a negative correlation with the enlargement
of the cariomyocyte nuclei (p < 0.05, r= −0.5), loss of car-
diomyocyte striation (p < 0.05, r = −0.44), cardiomyocyte
degeneration (p < 0.05, r = −0.53) and a positive correlation
with myocardial arterial narrowing (p < 0.05, r= 0.38).
Vimentin
In all the examined specimens, vimentin was expressed
within the interstitial tissue. The amount of vimentin-
positive cells differed between the examined groups. We
observed no difference in the intensity of the vimentin
staining in all the groups. A significantly higher percentage
Table 1 The results of immunohistochemical examination in studied dogs
Examined feature DCM MMVD control p-value
DES intensity; median (range) 1 (1–2)1 2 (1–3) 2 (2–3)1 1 0.006
DES %; average ± SD 85.8 ± 10.9 84.8 ± 9.3 82.2 ± 8.6
DES Remmele; median (range) 4 (3–8)1, 2 6 (4–9) 1 7 (6–10)2 1 0.03
2 0.001
DES desmosomes; median (range) 0 (0–3)1 2 (0–3) 2 (1–3)1 1 0.02
VIM intensity; median (range) 3 (2–3) 3 (2–3) 2 (2–3)
VIM %; average ± SD 15.3 ± 6.31,2 10.99 ± 5.71 10.5 ± 1.972 1 0.03
20.02
VIM Remmele; median (range) 4 (2–6) 3 (2–6) 4 (3–5)
PER intensity; median (range) 1 (0–2) 1 (1–2) 1 (1–1)
PER %; average ± SD 27.96 ± 27.61 46.4 ± 28.5 67.76 ± 9.71 1 0.03
PER Remmele; median (range) 2 (0–3) 3 (1–4) 3 (3–3)
CAS intensity; median (range) 1 (0–2) 1 (1–2) 1 (1–2)
CAS %; average ± SD 46.9 ± 25.11,2 73.6 ± 24.91 84.6 ± 8.92 1 0.01
2 0.01
CAS Remmele; median (range) 3 (1–4)1,2 4 (1–7)1 4 (3–9)2 1 0.01
2 0.01
DES desmin, VIM vimentin, PER periostin, CAS caspase, SD standard deviation, DCM dogs with dilated cardiomyopathy, MMVD dogs with myxomatous mitral valve
disease; superscripts (1,2) indicate values showing significant statistical difference.
All the cell markers were evaluated for: the intensity of expression (scored from 0: no expression to 3: strong expression), the percentage of cells showing positive
expression, as well as the Remmele score (scored from 0 to 12, taking into account both the intensity of expression and percentage of positive cells). Additionally
the cardiomyocyte desmosomes were evaluated for desmin expression from 0 (no visible desmosomes) to 3 (well visible desmosomes)
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of vimentin-positive cells was characteristic of the DCM
group as compared to the remaining two groups (Tables 1
and 2, Fig. 2).
The percentage of vimentin-positive cells showed a
negative correlation with perivascular fibrosis (p < 0.05,
r = −0.39), a positive correlation with the enlargement of
cardiomyocyte nuclei (p < 0.05, r = 0.34), and a negative
correlation with arterial narrowing (p < 0.05, r = −0.37).
The vimentin Remmele score showed a negative correl-
ation with perivascular fibrosis (p < 0.05, r = −0.33) and
with arterial narrowing (p < 0.05, r = −0.39).
Periostin
Periostin was expressed in the normal myocardium,
mainly in the cytoplasm of cardiomyocytes. There was
also mild expression in the interstitial tissue. 29.4% of
the MMVD specimens and 33.3% of the DCM speci-
mens showed a strong expression of periostin in the
interstitial tissue and only mild expression in the cardio-
myocyte cytoplasm. Approximately 30% of the speci-
mens in each group showed no expression of periostin.
At the same time, significantly fewer periostin-positive
cells were observed in the DCM group as compared to
the remaining two groups (Tables 1 and 2, Fig. 3).
Both the percentage of periostin-positive cells and the
periostin Remmele score showed a negative correlation
with the enlargement of the cardiomyocyte nuclei (p <
0.05, r = −0.3).
Caspase-3
Caspase-3 gave a strong diffuse cytoplasmic expression in
all the specimens from the control group. A similar expres-
sion was observed in 73.5% of dogs in the MMVD group
and in only 26.7% of dogs in the DCM group. The DCM
group showed a significantly lower percentage of caspase-
3-positive cells and a lower Remmele score as compared to
the remaining two groups (Tables 1 and 2, Fig. 4).
The intensity of the expression of caspase-3 showed a
negative correlation with the loss of striation (p < 0.05, r =
−0.28) and a positive correlation with the arterial narrow-
ing (p < 0.05, r = 0.51). Both the percentage of caspase-3-
positive cells and caspase-3 Remmele score showed a
negative correlation with the enlargement of cardiomyo-
cyte nuclei (p < 0.05, r = −0.44 and r = −0.47, respectively),
loss of striation (p < 0.05, r = −0.38 and r = −0.48, respect-
ively) and cardiomyocyte degeneration (p < 0.05, r = −0.36
and r = −0.43, respectively).
Discussion
Our study shows that although DCM and MMVD are
both accompanied by LA enlargement, there are various
Table 2 Type of the expression of cell markers in examined specimens in each group
Antibody Pattern of expression DCM (n; %) MMVD (n; %) Control (n; %)
DES Regular, well-preserved striation 3 (20%) 19 (55.9%) 7 (100%)
Irregular striation 9 (60%) 8 (23.5%) 0
No expression 3 (20%) 7 (20.6%) 0
DES (desm) Well-visible 3 (20%) 12 (35.3%) 7 (100%)
Faint 9 (60%) 14 (41.2%) 0
No expression 3 (20%) 8 (23.5%) 0
VIM Abundant between cardiomyocytes 5 (33.3%) 2 (5.9%) 1 (14.3%)
Sparse between cardiomyocytes 4 (26.7%) 26 (76.5%) 6 (85.7%)
No expression 6 (40%) 6 (17.6%) 0
PER Diffused cytoplasmic expression in cardiomyocytes
with mild expression in interstitial tissue
5 (33.3%) 15 (44.1%) 5 (71.4%)
Strong expression in interstitial tissue with mild
cytoplasmic expression in cardiomyocytes
5 (33.3%) 10 (29.4%) 0
No expression 5 (33.3%) 9 (26.5%) 2 (28.6%)
CAS Diffuse strong cytoplasmic expression 4 (26.7%) 25 (73.5%) 7 (100%)
Diffuse mild cytoplasmic expression 10 (66.7%) 6 (17.6%) 0
No expression 1 (6.7%) 3 (8.8%) 0
DES desmin, desm desmosomes, VIM vimentin, PER periostin, CAS caspase, DCM dogs with dilated cardiomyopathy, MMVD dogs with myxomatous mitral
valve disease
Desmin showed positive expression within the cardiomyocyte and was evaluated for the regularity and visibility of the cardiomyocyte cross-striation and for the
visibility of desmosomes within the cardiomyocyte; vimentin showed positive expression within the interstitial tissue and no expression within the cardiomyocyte;
periostin showed positive expression in both cardiomyocyte and interstitial tissue with variable intensity; caspase-3 showed positive expression only within the
cardiomyocyte. All the cell markers showed cytoplasmic expression
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changes occurring in the myocardium in the course of
these diseases, with more pronounced changes in cardio-
myocytes and interstitial tissue in DCM than MMVD.
During the progression of heart failure, the cross striation
and desmosomes became less organised. The amount of
interstitial tissue comprised of vimentin-positive cells in-
creased. These changes were more pronounced in the
Fig. 1 The cytoplasmic expression of desmin in cardiomyocyte (brown)
in examined groups (interstitial tissue stained blue; scale bar= 50 μm).
a – DCM group: the cardiomyocytes are swollen and show irregular
desmin expression scored 1 with no visible cross-striation; the
desmosomes are not visible (score 0); b – MMVD group:
cardiomyocyte with regular, well-preserved striation; the intensity
of desmin expression scored 3; desmosomes are well visible
(arrows; score 3); c – control group: cardiomyocyte with regular,
well-preserved striation; the intensity of desmin expression
scored 3; desmosomes are well visible (arrows; score 3)
Fig. 2 The cytoplasmic expression of vimentin (brown; arrows) in
interstitial tissue in examined groups (vimentin-negative cells stained
blue; scale bar= 50 μm). a – DCM group: abundant vimentin-positive
cells between cardiomyocyte; the vimentin-positive cells show staining
intensity scored 3; b – MMVD group: sparse vimentin-positive cells
between cardiomyocyte; the vimentin-positive cells show staining
intensity scored 3; c – control group: sparse vimentin-positive cells
between cardiomyocyte; the vimentin-positive cells show staining
intensity scored 3
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DCM group than in the MMVD group. With heart failure,
the structure of cardiomyocytes and intercalated disks
undergoes disorganisation, which leads to loss of myofila-
ments and their supporting proteins, e.g. desmin [14, 26].
Cardiomyocyte remodelling is accompanied by the
expansion of interstitial tissue with fibrosis and scar
formation [26]. The interstitial tissue in failing hearts con-
sists not only of mesenchymal cells, but also of collagens
and fibronectin [14]. That may explain why we did not find
Fig. 3 The cytoplasmic expression of periostin (brown) in examined
groups (periostin-negative cells stained blue; scale bar= 50 μm). a – DCM
group: strong expression in interstitial tissue (arrows) with intensity
scored 2; b – MMVD group: diffused cytoplasmic expression in
cardiomyocyte (*) with mild expression in interstitial tissue (arrows);
intensity of expression scored 1; c – control group: diffused cytoplasmic
expression in cardiomyocyte (*); intensity of expression scored 1
Fig. 4 The cytoplasmic expression of caspase-3 (brown) in examined
groups (caspase-3-negative cells stained blue; scale bar = 50 μm). a –
DCM group: diffuse mild cytoplasmic expression in cardiomyocyte
(*) scored 1; approximately 60% of cardiomyocyte showing positive
expression; b – MMVD group: diffuse strong cytoplasmic expression
in cardiomyocyte (*) scored 2; over 90% of cardiomyocyte show
positive expression; c – control group: diffuse strong cytoplasmic
expression in cardiomyocyte (*) scored 2; over 90% of cardiomyocyte
show positive expression
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a correlation between interstitial fibrosis and the percentage
of vimentin-positive cells although the number of those
cells was the highest in the DCM group.
The periostin showed variability in the expression
pattern. It changed from a cytoplasmic intra-cardiomyocyte
expression in the control group to an intense expression in
the interstitial tissue with only mild expression in the car-
diomyocyte cytoplasm present in the DCM and MMVD
group. Periostin undergoes upregulation in injured and re-
modelling tissues (including myocardium), [15, 17, 28]. It
binds to the extracellular matrix proteins and does not play
a direct structural role. Instead, it modulates the cell pheno-
type and function. It activates cardiac fibroblasts, inducing
their migration and transdifferentiation [15]. According to
Zhao et al. [28], the increase in interstitial periostin
expression shows a high correlation to heart fibrosis. We
evaluated both interstitial and cardiomyocyte periostin
expression and found no such relationship. However, both
greater interstitial fibrosis and more pronounced change in
the periostin expression pattern were found in the DCM
group than in the MMVD group.
The lower expression of caspase-3 noted in the
DCM group as compared to both the MMVD and
the control group contradicts the results of other
authors. An increased expression of caspsase-3 genes
was noted in tachycardia-induced heart failure [29–
31]. This may suggest that in DCM, frequently associ-
ated with tachyarrhythmias, apoptosis plays a key role
in myocardial failure. However, the caspase-3 antibody
used in our study was not specific for the inactive
and active protein. That finding, as well as the
marked caspase-3 expression in the control group,
changes in nuclei structure in heart failure, alterations
in transcription noted by other authors [26], and the
negative correlation between caspase-3 expression and
cardiomyocyte degeneration, all suggest that the
transcription of caspase-3 may be altered in DCM pa-
tients, thus leading to the use of all the available
cytoplasmic caspase-3. In other studies of over-
expression of caspase-3 in tachycardia-induced cardio-
myopathy, the animals usually underwent a post-mortem
examination after several weeks of the experiment [29–31].
The dogs in our study presented with stage D heart failure
resulting from heart disease that lasted months or years.
That may have contributed to the depletion of the available
cytoplasmic proteins. On the other hand, Schaper et al. [26]
hypothesise that apoptosis plays a minor role in heart failure.
Although the alterations in the expression of the
examined proteins were noted in both groups, they
were more pronounced in the DCM group than in the
MMVD group. In our previous research [10], we noted
that the atrial specimens from DCM dogs contained
more marked interstitial fibrosis and degeneration of
cardiomyocytes, as well as less pronounced perivascular
fibrosis and arterial narrowing compared to the MMVD
dogs. That finding, together with a lower expression of
desmin, vimentin, periostin and caspase-3 in the DCM
group than in the control and MMVD groups, explains
the negative correlation of the expression of those pro-
teins and the features of cardiomyocyte degeneration
(enlargement of the nuclei, loss of striation and struc-
tural changes) or perivascular fibrosis. It also explains
the positive correlation between the expression of the
markers and arterial narrowing.
Owing to the fact that the DCM and MMVD groups
did not show significant differences in the LA enlarge-
ment (no difference in the LA/Ao ratio between groups),
the significant differences in heart remodelling, including
differences in the expression of cell markers, indicate that
volume overload is not the only factor contributing to
myocardial remodelling in DCM. This may suggest a
potential role of sustained rhythm disturbances (frequent
in DCM and present in all of the examined cases in the
DCM group) or primary myocardial dysfunction leading
to chamber dilation (as in the ventricular myocardium in
dogs with DCM) in the remodelling of the LA in this
disease [5, 6].
The examined groups showed significant differences in
the expression of the examined proteins. Hence, further
studies will be focused on carrying out an analysis of
numerous cell markers in both cardiomyocytes and intersti-
tial tissue.
Conclusion
The expression of desmin, vimentin, periostin and caspase-
3 in the left atrium changed in both DCM and MMVD
compared to the normal myocardium. The alterations were
more pronounced in dogs with DCM than in those with
MMVD, and there was no difference in left atrial enlarge-
ment between the two groups. This suggests that although
both diseases lead to similar left atrial enlargement, the
mechanism of remodelling of LA myocardium varies
between DCM and MMVD and may be not only a result of
that enlargement resulting from volume overload.
Abbreviations
Ao: Aorta; DCM: Dilated cardiomyopathy; FS: Fractional shortening; LA: Left
atrium; LA/Ao: Left atrial-to-aortic root diameter ratio; MMVD: Myxomatous
mitral valve disease
Acknowledgements
We would like to thank the supporting staff of the Pathology Department of
Wroclaw University of Environmental and Life Sciences and of the Department of
Animal Sciences of University of Turin for their experienced technical assistance.
Availability of data and materials
Please contact author for data requests.
Funding
Not applicable.
Janus et al. Irish Veterinary Journal  (2016) 69:18 Page 8 of 9
Authors’ contributions
The ante-mortem examinations and treatment of the patients were performed
by ANN and UP, the post-mortem and histopathological examinations were
performed by IJ, MKG, RC, MT and MN. The immunohistochemical examination,
manuscript preparation and statistical analysis were performed by IJ. All the
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
According to Polish law [32], standard diagnostic procedures and studies
conducted on animal tissue do not require permission from the Ethical
Board. Oral consent for the clinical examination was obtained from all
owners, as those procedures are used routinely to diagnose canine heart
disease.
Author details
1Division of Pathomorphology and Veterinary Forensics, Department of
Pathology, Wroclaw University of Environmental and Life Sciences, Wroclaw
50375, Poland. 2Department of Internal Medicine and Clinic of Diseases of
Horses, Dogs and Cats, Wroclaw University of Environmental and Life
Sciences, Wroclaw 50366, Poland. 3Department of Animal Sciences, University
of Turin, Grugliasco, TO, Italy.
Received: 7 January 2016 Accepted: 15 November 2016
References
1. Alroy J, Rush JE, Freeman L, Amarendhra Kumar MS, Karuri A, Chase K, et al.
Inherited infantile dilated cardiomyopathy in dogs: genetic, clinical,
biochemical, and morphologic findings. Am J Med Gen. 2000;95(1):57–66.
2. Dambach DM, Lannon A, Sleeper MM, Buchanan J. Familial dilated
cardiomyopathy of young Portuguese Water Dogs. J Vet Intern Med. 1999;
13:65–71.
3. Dukes-McEwan J, Borgarelli M, Tidholm A, Vollmar AC, Häggström J.
Proposed guidelines for the diagnosis of canine idiopathic dilated
cardiomyopathy. J Vet Cardiol. 2003;11:7–19.
4. Lobo L, Carvalheira J, Canada N, Bussadori C, Gomes JL, Faustino AMR. Histologic
characterization of dilated cardiomyopathy in Estrela Mountain Dogs. Vet Pathol.
2010;47:637–42.
5. Tidholm A, Häggström J, Borgarelli M, Tarducci A. Canine idiopathic dilated
cardiomyopathy. Part I: aetiology, clinical characteristics, epidemiology and
pathology. Vet J. 2001;162:92–107.
6. Tidholm A, Jönsson L. Histologic characterization of canine dilated
cardiomyopathy. Vet Pathol. 2005;42:1–8.
7. Häggström J, Duelund Pedersen H, Kvart C. New insights into degenerative
mitral valve disease in dogs. Vet Clin North Am Small Anim Pract. 2004;
34(5):1209–26.
8. Hanna N, Cardin S, Leung T-K, Nattel S. Differences in atrial versus ventricular
remodelling in dogs with ventricular tachypacing-induced congestive heart
failure. Cardiovasc Res. 2004;63:236–44.
9. Janus I, Nowak M, Madej JA. Pathomorphological changes of the myocardium
in canine dilated cardiomyopathy. Bull Vet Inst Pulawy. 2015;59:135–42.
10. Janus I, Noszczyk Nowak A, Nowak M, Ciaputa R, Kandefer-Gola M,
Paslawska U. A comparison of the histopathologic pattern of the left atrium
in canine dilated cardiomyopathy and chronic mitral valve disease. BMC Vet Res.
2016;12(1):3.
11. Gofflot S, Kischel P, Thielen C, Radermacher V, Boniver J, De Leval L.
Characterisation of an antibody panel for immunohistochemical analysis of
canine muscle cells. Vet Immunol Immunop. 2008;125:225–33.
12. Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of cytoskeleton in
heart failure. Cardiovasc Res. 2000;45:273–8.
13. Pawlak A, Gil RJ. Desmin – an important structural protein of a cardiac myocyte.
Kadiol Pol. 2007;65:303–9.
14. Sharov VG, Kostin S, Todor A, Schaper J, Sabbath HN. Expression of cytoskeletal,
linkage and extracellular proteins in failing dog myocardium. Heart Fail Rev.
2005;10:297–303.
15. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease.
Physiol Rev. 2012;92:635–88.
16. Katsuragi N, Morishita R, Nakamura N, Ochiai T, Taniyama Y, Hasegawa Y, et
al. Periostin as a novel factor responsible for ventricular dilation. Circulation.
2004;110:1806–13.
17. Litvin J, Blagg A, Mu A, Matiwala S, Montgomery M, Berretta R, et al. Periostin
and periostin-like factor in the human heart: possible therapeutic targets.
Cardiovasc Pathol. 2006;15:24–32.
18. Stansfield WE, Andersen NM, Tang RH, Selzman CH. Periostin is a novel
factor in cardiac remodeling after experimental and clinical unloading of
the failing heart. Ann Thorac Surg. 2009;88:1916–21.
19. Regula KM, Kirshenbaum LA. Apoptosis of ventricular myocytes: a means to
an end. J Mol Cell Cardiol. 2005;38:3–13.
20. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of
caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.
21. Mughal W, Dhingra R, Kirchenbaum LA. Striking a balance: autophagy,
apoptosis, and necrosis in a normal and failing heart. Curr Hypotens Rep.
2012;14:540–7.
22. Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, et al.
Survival characteristics and prognostic variables of dogs with mitral
regurgitation attributable to myxomatous valve disease. J Vet Intern Med.
2008;22:120–8.
23. Whitney JC. Cardiovascular pathology. J Small Anim Pract. 1967;8(8):459–65.
24. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Häggström J, et al.
Guidelines for the diagnosis and treatment of canine chronic valvular heart
disease. J Vet Intern Med. 2009;23(6):1142–50.
25. Falk T, Jönsson L, Olsen LH, Pedersen HD. Arteriosclerotic changes in the
myocardium, lung and kidney in dogs with chronic congestive heart failure
and myxomatous mitral valve disease. Cardiovasc Pathol. 2006;15:185–93.
26. Schaper J, Kostin S, Hein S, Elsässer A, Arnon E, Zimmermann R. Structural
remodelling in heart failure. Exp Clin Cardiol. 2002;7(2/3):64–8.
27. Remmele W, Stegner HE. Recommendation for uniform definition of an
immunoreactive score (IRS) for immunohistochemical estrogen receptor
detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–40.
28. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is
upregulated and associated with myocardial fibrosis in human failing hearts.
J Cardiol. 2014;63:373–8.
29. Mahmoudabady M, Niazmand S, Shafei MN, McEntee K. Investigation of
apoptosis in a canine model of chronic heart failure induced by tachycardia.
Acta Physiol Hung. 2013;100(4):435–44.
30. Moe GW, Naik G, Konig A, Lu X, Feng Q. Early and persistent activation of
myocardial apoptosis, bax and caspases: insights into mechanisms of
progression of heart failure. Pathophysiology. 2002;8:183–92.
31. Heinke MY, Yao M, Chang D, Einstein R, Dos Remedios CG. Apoptosis of
ventricular and atrial myocytes from pacing-induced canine heart failure.
Cardiovasc Res. 2001;49:127–34.
32. The Polish Parliament: Act on the protection of animals used for scientific or
educational purposes. http://orka.sejm.gov.pl/proc7.nsf/ustawy/2709_u.htm
(2015). Accessed 14 Sept 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Janus et al. Irish Veterinary Journal  (2016) 69:18 Page 9 of 9
